| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,750,000 |
| Market
Cap: |
184.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.77 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.5 |
| Insider 6 Months : 12.5 |
| Insider 3/6 Months : 25.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
68,600 |
68,600 |
96,450 |
225,574 |
| Total Buy Value |
$872,910 |
$872,910 |
$1,130,787 |
$2,406,697 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
8 |
8 |
23 |
59 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Snehal |
CEO and CFO |
• • • |
2023-04-18 |
4 |
B |
$11.12 |
$22,240 |
D/D |
2,000 |
5,279,177 |
3.15 |
-17% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-04-11 |
4 |
B |
$12.42 |
$62,100 |
D/D |
5,000 |
5,271,177 |
3.23 |
-22% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-04-11 |
4 |
B |
$11.87 |
$11,870 |
D/D |
1,000 |
258,745 |
2.74 |
-22% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-03-15 |
4 |
B |
$12.71 |
$3,178 |
D/D |
250 |
257,745 |
2.66 |
-30% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-03-10 |
4 |
B |
$12.12 |
$12,120 |
D/D |
1,000 |
2,737,486 |
3.15 |
-25% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-02-24 |
4 |
B |
$15.40 |
$3,849 |
D/D |
250 |
257,495 |
2.66 |
-39% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-02-17 |
4 |
B |
$16.53 |
$9,918 |
D/D |
600 |
2,736,486 |
3.15 |
-41% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-02-10 |
4 |
B |
$18.68 |
$18,680 |
D/D |
1,000 |
2,735,886 |
3.15 |
-46% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-02-03 |
4 |
B |
$20.84 |
$5,210 |
D/D |
250 |
257,245 |
2.74 |
-45% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-01-27 |
4 |
B |
$19.35 |
$38,700 |
D/D |
2,000 |
2,734,886 |
3.23 |
-41% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-01-27 |
4 |
B |
$19.20 |
$4,800 |
D/D |
250 |
256,995 |
2.66 |
-41% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-01-20 |
4 |
B |
$17.37 |
$26,055 |
D/D |
1,500 |
2,732,886 |
3.23 |
-38% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-01-13 |
4 |
B |
$16.50 |
$4,125 |
D/D |
250 |
256,745 |
2.66 |
-30% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-01-06 |
4 |
B |
$15.18 |
$22,770 |
D/D |
1,500 |
2,731,386 |
3.15 |
-21% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-12-29 |
4 |
B |
$15.19 |
$60,760 |
D/D |
4,000 |
2,729,886 |
3.23 |
-28% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-12-16 |
4 |
B |
$13.01 |
$13,010 |
D/D |
1,000 |
2,725,886 |
3.15 |
-16% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2022-12-16 |
4 |
B |
$12.94 |
$3,235 |
D/D |
250 |
256,495 |
2.66 |
-16% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-12-09 |
4 |
B |
$13.11 |
$26,220 |
D/D |
2,000 |
2,724,886 |
3.23 |
-11% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-12-02 |
4 |
B |
$13.84 |
$13,840 |
D/D |
1,000 |
2,722,886 |
3.15 |
-14% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2022-12-02 |
4 |
B |
$13.98 |
$3,495 |
D/D |
250 |
256,245 |
2.66 |
-14% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-11-02 |
4 |
B |
$8.79 |
$17,580 |
D/D |
2,000 |
2,721,886 |
3.15 |
47% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-10-14 |
4 |
B |
$9.75 |
$29,250 |
D/D |
3,000 |
2,719,886 |
3.23 |
58% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-10-07 |
4 |
B |
$9.72 |
$19,440 |
D/D |
2,000 |
2,716,886 |
3.15 |
58% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-09-30 |
4 |
B |
$9.46 |
$9,460 |
D/D |
1,000 |
2,714,886 |
3.15 |
93% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-09-29 |
4 |
B |
$9.23 |
$9,230 |
D/D |
1,000 |
2,713,886 |
3.15 |
99% |
|
106 Records found
|
|
Page 2 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.30 (2.03%) 
